Literature DB >> 17328075

RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.

Kelly A Rouster-Stevens1, Craig B Langman, Heather E Price, Roopa Seshadri, Richard M Shore, Kathy Abbott, Lauren M Pachman.   

Abstract

OBJECTIVE: To determine bone mineral density (BMD) in patients at the time of diagnosis of juvenile dermatomyositis (DM), to compare the RANKL:osteoprotegerin (OPG) ratio in patients with juvenile DM with that in healthy control subjects, and to evaluate whether BMD is associated with the RANKL:OPG ratio and the duration of untreated disease.
METHODS: Thirty-seven children with juvenile DM were enrolled. Dual x-ray absorptiometry (DXA) was performed before treatment, and Z scores for the lumbar spine (L1-L4) were determined. The duration of untreated disease was defined as the period of time from the onset of rash or weakness to the time at which DXA was performed. Serum specimens obtained at the time of DXA were analyzed for concentrations of RANKL and OPG, using enzyme-linked immunosorbent assay. The RANKL:OPG ratio was also determined in 44 age-matched healthy control subjects.
RESULTS: At the time of diagnosis of juvenile DM, patients had a significantly increased RANKL:OPG ratio compared with that in healthy children (mean +/- SD 2.19 +/- 3.03 and 0.13 +/- 0.17, respectively; P < 0.0001). In patients with a lumbar spine BMD Z score of -1.5 or lower, the RANKL:OPG ratio was significantly higher than that in patients with a lumbar spine BMD Z score higher than -1.5 (P = 0.038). Lumbar spine BMD Z scores (mean +/- SD -0.13 +/- 1.19 [range -2.10 to 2.85]) were inversely associated with the duration of untreated disease (R = -0.50, P = 0.003).
CONCLUSION: Children with juvenile DM have an elevated RANKL:OPG ratio at the time of diagnosis, resulting in expansion of the number of osteoclasts and activation of the bone resorptive function. This may lead to a lack of normal bone mineral accretion and a subsequent reduction in the lumbar spine BMD Z score. Patients with a longer duration of untreated juvenile DM have reduced lumbar spine BMD Z scores. These data suggest that early diagnosis could reduce the likelihood of reduced lumbar spine BMD in these patients by prompting intervention strategies at an early stage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17328075     DOI: 10.1002/art.22433

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

1.  Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.

Authors:  Kelly A Rouster-Stevens; Gabrielle A Morgan; Deli Wang; Lauren M Pachman
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-10       Impact factor: 4.794

2.  Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.

Authors:  Erin Kim; Joan Cook-Mills; Gabrielle Morgan; Simone T Sredni; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2012-11

3.  Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders.

Authors:  A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

Review 4.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

Review 5.  Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.

Authors:  Emily von Scheven; Kathleen Jo Corbin; Stefano Stagi; Stagi Stefano; Rolando Cimaz
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

6.  Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease.

Authors:  Yongdong Zhao; Tamara O Fedczyna; Violet McVicker; Jan Caliendo; Honglin Li; Lauren M Pachman
Journal:  Clin Immunol       Date:  2007-08-20       Impact factor: 3.969

7.  Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study.

Authors:  J Tamaki; M Iki; A Morita; Y Ikeda; Y Sato; E Kajita; S Kagamimori; Y Kagawa; H Yoneshima
Journal:  Osteoporos Int       Date:  2009-05-30       Impact factor: 4.507

Review 8.  Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

Authors:  Melody P Chung; Carrie Richardson; David Kirakossian; Amir B Orandi; Lesley A Saketkoo; Lisa G Rider; Adam Schiffenbauer; Carlos A von Mühlen; Lorinda Chung
Journal:  Autoimmun Rev       Date:  2020-03-28       Impact factor: 9.754

9.  Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study.

Authors:  Gunhild Lien; Thor Ueland; Kristin Godang; Anne M Selvaag; Oystein T Førre; Berit Flatø
Journal:  Pediatr Rheumatol Online J       Date:  2010-12-06       Impact factor: 3.054

10.  Secondary osteoporosis in patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova Maresova
Journal:  J Osteoporos       Date:  2011-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.